Moderna secures US approval for its first mRNA flu vaccine for adults 50+, overcoming initial Trump administration hesitations
Executive summary: Moderna obtained US regulatory approval for its first mRNA influenza vaccine, authorized for adults aged 50 and above, after earlier reservations from the Trump administration. This approval validates Moderna’s mRNA platform beyond COVID-19, opening a major market in seasonal flu prevention and potentially shifting dynamics in the vaccine industry.
Who is involved: Moderna, US Food and Drug Administration (FDA), and public health authorities overseeing vaccine authorization.
Likely next: Launch of the vaccine in US markets, potential expansion to younger age groups, and increased competition with established flu vaccine producers like Sanofi, GSK, and CSL Seqirus.
Moderna has received authorization from the US administration for its mRNA-based influenza vaccine, initially met with reluctance during the Trump era but now cleared for use in adults aged 50 and older. The approval marks a milestone in Moderna’s expansion beyond COVID-19 vaccines into seasonal infectious disease prevention using its mRNA platform. The decision follows positive clinical data and regulatory review, signaling confidence in the technology’s applicability to flu prophylaxis. This development could accelerate adoption of mRNA vaccines in routine immunization schedules and increase competitive pressure on traditional flu vaccine manufacturers.
Timeline
- — Vaccin contre la grippe : Moderna obtient l’aval de l’administration américaine pour son premier sérum à ARNm (Le Figaro — Économie)
Analysis — what this means
Likely next events
- Moderna to begin commercial distribution of the mRNA flu vaccine in the US Q4 2026
- FDA to review pediatric indications for the vaccine by mid-2027
- Sanofi and GSK to announce updated mRNA flu vaccine timelines by Q1 2027
Sectors affected
- Pharmaceuticals
- Vaccines
- mRNA therapeutics
Regulatory implications
- CDC likely to include Moderna’s flu vaccine in seasonal immunization recommendations for 50+
- HHS to monitor real-world effectiveness and safety post-licensure
Historical parallels
- FDA approval of first mRNA COVID-19 vaccines (Pfizer/BioNTech, Moderna) in December 2020
- Licensure of FluMist quadrivalent nasal spray vaccine in 2003 as a non-egg-based flu alternative
- Approval of Shingrix recombinant zoster vaccine in 2017, marking a shift to subunit vaccine technology
Key entities
Sources
Open the full interactive case file on Beyond →